We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Winter Respiratory Infections Linked to Vitamin D Levels

By LabMedica International staff writers
Posted on 30 Jun 2010
The increased incidence of influenza and other viral respiratory tract infections during the winter months may be linked to decreased levels of vitamin D.

Investigators at the Yale University School of Medicine (New Haven, CT, USA) determined serial monthly concentrations of 25-hydroxyvitamin D during the fall and winter 2009–2010 in 198 healthy adults, who did not know which serum components were being measured. More...
The participants were evaluated for the development of any acute respiratory tract infections by investigators who did not know the patients' 25-hydroxyvitamin D concentrations.

Results published in the June 14, 2010, online edition of the journal PloS ONE revealed that 18 participants maintained vitamin D levels of 38 ng/mL or higher during the study period. Of this group only three (16.6 %) developed viral infections. Of the 180 other participants, 81 (45 %) developed viral infections. Those with the higher vitamin D levels also experienced a marked reduction in the number of days required to recover from their respiratory infections.

The investigators concluded that, "Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/mL or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones. The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza.”

Related Links:

Yale University School of Medicine




Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.